PMI considers restarting production in Ukraine

May.24.2023
PMI considers restarting production in Ukraine
Philip Morris International considers restarting production in Ukraine despite security concerns and decreased sales.

In a recent interview with Interfax Ukraine, Massimo Andolina, the European Regional President of Philip Morris International (PMI), discussed the impact of Russia's invasion on multinational corporations in Ukraine. Andolina stated that PMI is exploring plans to restore production in Ukraine.


PMI has ceased production at its factory in Kharkiv due to ongoing security concerns resulting from the ongoing conflict. Currently, the company's brands in Ukraine are being temporarily produced by Imperial Tobacco. However, PMI intends to establish its own production facility in Ukraine.


Maximo Andolina emphasized two reasons for the decision: first, the desire to produce PMI's own products locally, and secondly, the company's commitment to investing in Ukraine even during times of war. He stated that PMI is actively exploring various alternative options for establishing new production facilities and plans to make relevant announcements in the near future.


The interview also touched on the decrease in PMI sales in the Ukrainian market. Massimo Andolina mentioned two factors: some people leaving the country or residing in occupied territory, resulting in consumer loss, and competition from illegal products. He stated that PMI has discussed with the government to address this issue and expressed confidence in the government's commitment to combating corruption and criminal activity. The company expects significant progress in combating illegal trade in the coming years.


Maximo Adonilna also shared his opinion on the government's decision to tax cigarettes and heated non-burning products. He stated that PMI believes these products should be considered different categories and taxed accordingly. They have noticed the success of heated tobacco products in the Ukrainian market and emphasized the necessity for differentiated tax treatment.


During the interview, the position of PMI in Russia was also addressed. According to Massimo Andolina, the company's top priority during the war was the protection of its Ukrainian employees' safety. Therefore, they temporarily suspended their investments in Russia and reduced their business operations. Despite PMI's previous announcement of its intention to withdraw from the Russian market, the changing regulatory environment has made it challenging for the company, which has significant business and assets in the country, to do so.


Reference List:


PMI is considering restarting production in Ukraine.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Philippines Draft Order Would Bring Nicotine Pouches Under PS Licensing Scheme
Philippines Draft Order Would Bring Nicotine Pouches Under PS Licensing Scheme
The Philippine Department of Trade and Industry is planning to impose mandatory product certification on nicotine pouches in an effort to curb illicit nicotine product trade.
Apr.13 by 2FIRSTS.ai
The new regulations on nicotine in Argentina are creating caution, expectations, and doubts about the market, according to a local reference in harm reduction for smoking.
The new regulations on nicotine in Argentina are creating caution, expectations, and doubts about the market, according to a local reference in harm reduction for smoking.
The new Argentine framework for tobacco and nicotine marks a shift from prohibition towards registration, traceability, and health surveillance. Juan Facundo Teme told 2Firsts that adult consumers and some of the commercial sector are cautiously optimistic, although concerns remain about flavors, registration costs, and market access.
May.11
From Brands to Supply Chains: 2Firsts Builds a PMTA Compliance Service System for the U.S. Market
From Brands to Supply Chains: 2Firsts Builds a PMTA Compliance Service System for the U.S. Market
2Firsts supports new tobacco and nicotine companies entering the U.S. market with full-chain PMTA compliance services.
Jun.04
FDA Adds 18 Tobacco Harmful Constituents and Seeks Comment on 3 More
FDA Adds 18 Tobacco Harmful Constituents and Seeks Comment on 3 More
U.S. Food and Drug Administration published a Federal Register notice finalizing the addition of 18 constituents to the established list of Harmful and Potentially Harmful Constituents in tobacco products. With the update, the list now contains 111 constituents. FDA also proposed adding three more constituents to the list and opened a public comment period ending at 11:59 p.m. ET on May 26, 2026.
Apr.24 by 2FIRSTS.ai
Thailand’s DDC Reaffirms Nicotine Pouches Are Regulated Under the Tobacco Products Control Act
Thailand’s DDC Reaffirms Nicotine Pouches Are Regulated Under the Tobacco Products Control Act
Thailand’s Department of Disease Control has warned the public not to believe claims that nicotine pouches are harmless, saying the products contain high levels of nicotine that can enter the bloodstream through the mouth lining and affect the nervous system and brain.
Apr.30 by 2FIRSTS.ai
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai